160 related articles for article (PubMed ID: 33565118)
21. Preferences for antimuscarinic therapy for overactive bladder.
Swinburn P; Lloyd A; Ali S; Hashmi N; Newal D; Najib H
BJU Int; 2011 Sep; 108(6):868-73. PubMed ID: 21105989
[TBL] [Abstract][Full Text] [Related]
22. Communicating with mismatch and tension: treatment provision experiences of primary care doctors treating patients with overactive bladder in Hong Kong.
Siu JY
BMC Fam Pract; 2015 Oct; 16():160. PubMed ID: 26519163
[TBL] [Abstract][Full Text] [Related]
23. The Usability and Feasibility of Conjoint Analysis to Elicit Preferences for Distal Radius Fractures in Patients 55 Years and Older.
Shapiro LM; Eppler SL; Baker LC; Harris AS; Gardner MJ; Kamal RN
J Hand Surg Am; 2019 Oct; 44(10):846-852. PubMed ID: 31495523
[TBL] [Abstract][Full Text] [Related]
24. Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder.
Barsdorf AI; Carlsson M; Bushmakin AG; Quinn S; Cappelleri JC; Pleil A
Int Urogynecol J; 2017 Dec; 28(12):1857-1863. PubMed ID: 28378111
[TBL] [Abstract][Full Text] [Related]
25. The responsiveness of the OAB-q among OAB patient subgroups.
Coyne KS; Matza LS; Thompson C; Jumadilova Z; Bavendam T
Neurourol Urodyn; 2007; 26(2):196-203. PubMed ID: 17016794
[TBL] [Abstract][Full Text] [Related]
26. The Feasibility and Usability of a Ranking Tool to Elicit Patient Preferences for the Treatment of Trigger Finger.
Shapiro LM; Eppler SL; Kamal RN
J Hand Surg Am; 2019 Jun; 44(6):480-486.e1. PubMed ID: 30797655
[TBL] [Abstract][Full Text] [Related]
27. Patient and physician decision-making dynamics in overactive bladder care: A mixed methods study.
Sitto HM; Brodsky CN; Wittmann D; Wallner LP; Streur C; DeJonckheere M; Stoffel JS; Cameron AP; Sarma A; Quentin Clemens J; Ippolito GM
Neurourol Urodyn; 2024 Mar; 43(3):565-573. PubMed ID: 38334205
[TBL] [Abstract][Full Text] [Related]
28. Patient-reported outcomes with the β
Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
[TBL] [Abstract][Full Text] [Related]
29. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder.
Cameron AP; Chung DE; Dielubanza EJ; Enemchukwu E; Ginsberg DA; Helfand BT; Linder BJ; Reynolds WS; Rovner ES; Souter L; Suskind AM; Takacs E; Welk B; Smith AL
J Urol; 2024 Jul; 212(1):11-20. PubMed ID: 38651651
[TBL] [Abstract][Full Text] [Related]
30. Psychometric properties of the incontinence utility index among patients with idiopathic overactive bladder: data from two multicenter, double-blind, randomized, Phase 3, placebo-controlled clinical trials.
Castejón N; Khalaf K; Ni Q; Cuervo J; Patrick DL
Health Qual Life Outcomes; 2015 Aug; 13():116. PubMed ID: 26231052
[TBL] [Abstract][Full Text] [Related]
31. Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder.
Jimenez-Cidre M; Costa P; Ng-Mak D; Sahai A; Degboe A; Smith CP; Tsai K; Herschorn S
Curr Med Res Opin; 2014 Aug; 30(8):1557-64. PubMed ID: 24762033
[TBL] [Abstract][Full Text] [Related]
32. The validation of the Dutch OAB-q SF: An overactive bladder symptom bother and health-related quality of life short-form questionnaire.
Groenendijk IM; Scheepe JR; Noordhoff TC; Blok BFM
Neurourol Urodyn; 2019 Aug; 38(6):1775-1782. PubMed ID: 31215693
[TBL] [Abstract][Full Text] [Related]
33. Predictors of discontinuing overactive bladder medications.
Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
[TBL] [Abstract][Full Text] [Related]
34. Psychosocial factors related to the use of InterStim® for the treatment of refractory overactive bladder.
Levin PJ; Siddiqui NY; Wu JM; Amundsen CL
Female Pelvic Med Reconstr Surg; 2014; 20(5):272-5. PubMed ID: 25181377
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of acupuncture for elderly overactive bladder population in Hong Kong: study protocol for a randomized controlled trial.
Chan YT; Zhang HW; Guo YQ; Chan TNH; Kwan YK; Lee CK; Ngan K; Lin ZX
Trials; 2018 Jul; 19(1):376. PubMed ID: 30005707
[TBL] [Abstract][Full Text] [Related]
36. Older People's Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment.
Decalf VH; Huion AMJ; Benoit DF; Denys MA; Petrovic M; Everaert KCMM
Drugs Aging; 2017 Aug; 34(8):615-623. PubMed ID: 28656509
[TBL] [Abstract][Full Text] [Related]
37. Systemic Nonurological Symptoms in Patients with Overactive Bladder.
Lai HH; Vetter J; Jain S; Andriole GL
J Urol; 2016 Aug; 196(2):467-72. PubMed ID: 26997309
[TBL] [Abstract][Full Text] [Related]
38. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis.
Balzarro M; Rubilotta E; Mancini V; Trabacchin N; Oppezzi L; Li Marzi V; Fusco F; Serati M
Sex Med Rev; 2019 Oct; 7(4):565-574. PubMed ID: 31326358
[TBL] [Abstract][Full Text] [Related]
39. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS.
Coyne KS; Sexton CC; Kopp ZS; Ebel-Bitoun C; Milsom I; Chapple C
BJU Int; 2011 Nov; 108(9):1459-71. PubMed ID: 21371240
[TBL] [Abstract][Full Text] [Related]
40. A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints.
Heesakkers JPFA; Digesu GA; van Breda J; Van Kerrebroeck P; Elneil S
Neurourol Urodyn; 2018 Mar; 37(3):1060-1067. PubMed ID: 28892221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
